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Abstract: CRISPR activation (CRISPRa) has revealed great potential as a tool to modulate the
expression of targeted cellular genes. Here, we successfully applied the CRISPRa system to trigger the
Kaposi’s sarcoma-associated herpesvirus (KSHV) reactivation in latently infected cells by selectively
activating ORF50 gene directly from the virus genome. We found that a nuclease-deficient Cas9
(dCas9) fused to a destabilization domain (DD) and 12 copies of the VP16 activation domain (VP192)
triggered a more efficient KSHV lytic cycle and virus production when guided to two different sites
on the ORF50 promoter, instead of only a single site. To our surprise, the virus reactivation induced
by binding of the stable DD-dCas9-VP192 on the ORF50 promoter was even more efficient than
reactivation induced by ectopic expression of ORF50. This suggests that recruitment of additional
transcriptional activators to the ORF50 promoter, in addition to ORF50 itself, are needed for the
efficient virus production. Further, we show that CRISPRa can be applied to selectively express the
early lytic gene, ORF57, without disturbing the viral latency. Therefore, CRISPRa-based systems can
be utilized to facilitate virus–host interaction studies by controlling the expression of not only cellular
but also of specific KSHV genes.
Keywords: KSHV; dCas9; CRISPRa; DD-dCas9-VP192; ORF50; RTA; KSHV lytic cycle; KSHV
reactivation; Kaposi’s sarcoma-associated herpesvirus
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1. Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV) has been etiologically linked to three
malignancies, namely Kaposi sarcoma (KS), primary effusion lymphoma (PEL), the plasmablastic
variant of multicentric Castleman disease (MCD) and also to two systemic inflammatory
diseases: KSHV-inflammatory cytokine syndrome (KICS) and KS immune reconstitution syndrome
(KS-IRIS) [1–5]. While PEL is a B cell tumor in which the virus is found predominantly in a latent
form, KSHV lytic reactivation is involved in the pathogenesis of the other KSHV-related diseases [6–9].
Therefore, profound understanding of the KSHV reactivation is required for the successful management
of the KSHV-related diseases.
KSHV lytic cycle is initiated by the expression of the replication and transcription activator (RTA)
protein encoded by the ORF50 viral gene [9,10]. It has been demonstrated that ORF50 expression
is necessary and sufficient to trigger the complete lytic replication cycle which culminates with the
production and release of infectious viral progeny [9,10]. In culture, KSHV establishes latency in
virtually all cell types with a few exceptions. As for instance, in lymphatic endothelial cells KSHV
undergoes asynchronous and spontaneous lytic reactivation in a subset of infected cells resulting in
the production of high titers of infectious virus [11,12].
In the past years, different chemicals such as TPA (12-O-Tetradecanoylphorbol 13-acetate) and
sodium butyrate have been used to break the latency and trigger the KSHV lytic cascade [13,14].
However, these substances have broad effects on the cellular physiology, TPA being an activator of
protein kinase C and of NF-kB, and sodium butyrate being a broad histone deacetylase inhibitor. A
major advance for studies on KSHV lytic replication has been the generation of two systems: the
PEL-derived BCBL1-TREX-RTA and the cancer-derived iSLK.219 [15,16]. Both these cell lines rely
on the ectopic expression of ORF50 from a doxycycline-inducible promoter to trigger the KSHV lytic
replication cycle. Regardless, to date, we are still missing cellular systems where the KSHV lytic cycle
can be activated by governing the ORF50 expression directly from the viral genome.
CRISPR activation (CRISPRa) systems are derived from the Streptococcus pyogenes CRISPR-Cas9,
which can introduce double strand breaks when targeted to specific DNA sites by guide RNAs [17,18].
In the CRISPRa, the Cas9 enzyme is devoid of nuclease activity due to point mutations in the
nuclease domain (dead Cas9 = dCas9) and it is fused to transcriptional activators. The use of this
engineered, repurposed dCas9, guided to bind at promoters by single-guide RNAs (sgRNAs) has
allowed modulation of targeted gene expression [18–20]. Furthermore, this highly versatile system
has also been used to simultaneously switch on the expression of several genes to drive cellular
reprogramming [21–23].
In this study, we have used a dCas9 fused to multiple copies of the herpes simplex 1 (HSV-1) VP16
activator domain to trigger the activation of the lytic ORF50 and ORF57 gene expression in latently
KSHV-infected cells. We show that the dCas9-activator protein can efficiently activate both viral genes.
While ORF50 gene expression activation triggered the full KSHV lytic cycle and virus production,
ORF57 activation did not disturb viral latency.
2. Materials and Methods
2.1. Cells and DNA Transfection
HEK293 (a kind gift from Tomi Mäkelä, University of Helsinki, Finland) and U2OS (ATCC,
Manassas, VA, USA) cells were maintained in DMEM supplemented with 10% fetal calf serum,
L-glutamine and Penicillin/Streptomycin. To transfect plasmid DNA into the cells, Fugene 6 HD
(Promega, Madison, WI, USA) or JETOptimus (Polyplus, Illkirch, France) were used following
instructions provided by the manufacturer. Where indicated, trimethoprim (TMP, Sigma, St. Louis,
MO, USA) was added to stabilize DD-dCas9-VP192 protein.
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2.2. Generation of DNA Constructs
ORF50 was amplified from KSHV-BAC16 [24] with primers RTAins-Fw and -Rv
(5′-aggacctgggctcaggatctgcgcaagatgacaagggtaagaagcttcggcggtc-3′; 5′-gatatcgaattcggcgcgcctcagtctc
ggaagtaattacgcc-3′) and the pFUW-myc backbone was amplified from pFUW-Myc-mCherry [25] by PCR
and using primers pFUW-Myc-BB-Fw and -Rv (5′-agatcctgagcccaggtcctc-3′; 5′-ggcgcgccgaattcgatatc-3′).
The DNA fragments were fused together using the HiFi assembly master mix (NEB, Ipswich, MA,
USA) and transformed in competent bacteria.
sgRNA spacer sequences that bind to ORF50 and ORF57 promoters were designed using the
tools in CRISPR website (www.crispr.mit.edu). The generation of the DNA fragment containing U6
promoters and sgRNA was conducted as described in Balboa et al. [21] using the following sequences
as sgRNA oligos (underlined–sgRNA spacer):
sg50-1 (5′-gtggaaaggacgaaacaccgtcatctccaatacccggaatgttttagagctagaaatag-3′)
sg50-2 (5′-gtggaaaggacgaaacaccggttcagtcacatgtacgctagttttagagctagaaatag-3′)
sg50-3 (5′-gtggaaaggacgaaacaccgatgagtcgccggtagctgccgttttagagctagaaatag-3′)
sg50-4 (5′-gtggaaaggacgaaacaccgccgcccagaaaccagtagctgttttagagctagaaatag-3′)
sg57-1 (5′-gtggaaaggacgaaacaccgccaaaatagcccgcggcatagttttagagctagaaatag-3′)
sg57-2 (5′-gtggaaaggacgaaacaccgcacggcccatttttcgtttggttttagagctagaaatag-3′)
sg57-3 (5′-gtggaaaggacgaaacaccgcattagggtgagcgaagtcagttttagagctagaaatag-3′)
sg57-4 (5′-gtggaaaggacgaaacaccggttaatcccactatataaccgttttagagctagaaatag-3′)
Afterwards, the U6-sgRNA fragment was amplified with primers Ins-u6-grna-Fw and -Rv
(5′-cgcaattaaccctcactaaagagggcctatttcccatgattcc-3′; 5′-gatgagtttggacaaaccacgcgtcgacagatctcgtctc-3′)
and the backbone from pLenti6.3-GFP (provided by GBU, University of Helsinki, Finland)
was amplified with primers: BB-Lenti-pcdna-Fw and -Rv (5′-gtggtttgtccaaactcatcaatgtatc-3′;
5′-tttagtgagggttaattgcgcgc-3′). The DNA fragments were fused together using the HiFi assembly
master mix (NEB) and transformed in competent bacteria. The generated vectors were analyzed by
restriction enzymes and the inserts were verified by Sanger sequencing.
2.3. Generation of HEK293-DD-dCas9-VP192_rKSHV.219 Cell Line
To generate HEK293 cells stably expressing DD-dCas9-VP192, the cells were transfected with
PB-CAG-DDdCas9VP192-T2A-GFP-IRES-Neo (also deposited in Addgene #102885) together with a
vector expressing PiggyBac Transposase as in [21]. The cells were selected in media containing G418
(400 µg/mL). In addition, cells expressing high levels of EGFP, which are also the cells expressing
high levels of DD-dCas9-VP192, were sorted using a BD FACSAria II sorter. Prior to sorting, cells
were passed through a 40-µm strainer (BD biosciences, Franklin Lakes, NJ, USA) and resuspended
in PBS containing 1% fetal calf serum and 2 mM EDTA. Sorted cells were analyzed after expansion
by flow cytometry and found mostly GFP-positive (approx. 94%). Next, sorted cells were infected
with rKSHV.219 [26] and maintained in media containing G418 (400 µg/mL) and puromycin (5 µg/mL).
rKSHV.219 virus production from iSLK.219 and concentration has been described previously [25].
2.4. Immunoblotting
Proteins were separated in 4–15% Criterion TGX gels (Bio-Rad, Hercules, CA, USA) and transferred
to Trans Blot Turbo Midi Nitrocellulose membranes (Bio-Rad). The membranes were blocked with
5% non-fat dry milk in TBS-T. Antibodies detecting target proteins were diluted in 5% non-fat dry
milk in TBS-T and incubated overnight, at 4 ◦C. Antibodies detecting ORF57 (sc-135746), ORF45
(sc-53883), K8.1 (sc-65446), Actin (sc-8432) were from Santa Cruz Biotechnology (SCBT, Dallas, TX,
USA). Antibodies detecting HA tag (HA.11) were from Biolegend (San Diego, CA, USA), Myc-tag
(9B11) from Cell Signaling Technology (Danvers, MA, USA) and ORF50 was a gift from Carolina Arias
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(UC Santa Barbara, Santa Barbara, CA, USA). Anti-Rabbit IgG HRP-linked (7074S) and anti-Mouse
IgG HRP-linked (7076S) secondary antibodies were from Cell Signaling Technology. WesternBright
Sirius HRP substrate (Advansta, San Jose, CA, USA) was used for revealing the protein bands during
imaging in a ChemiDoc gel imaging system (Bio-Rad).
2.5. Immunofluorescence Analysis
Cell were fixed in 4% paraformaldehyde or cold methanol, washed with PBS, permeabilized with
PBS containing 0.2% Triton-X100 and blocked with PBS containing 0.2% Triton X-100 and 1% bovine
serum albumin (BSA). Antibodies detecting HA tag (HA.11) were from Biolegend, anti-ORF50 was
a gift from Carolina Arias (UC Santa Barbara, USA) and anti-EGFP was a kind gift from J. Mercer
(Institute of Microbiology and Infection, University of Birmingham, UK). Secondary antibodies coupled
to Alexa Fluor 488, 555 and 647 were from Thermo Fischer Scientific (Waltham, MA, USA). Nuclei were
counterstained with Hoechst 33342 (1 µg/mL, Sigma, St. Louis, MO, USA). Images were acquired using
an ImageXpress Pico microscope (Molecular Devices, San Jose, CA, USA), CellInsight High throughput
microscope (Thermo Fischer Scientific) or Eclipse Ts2-FL inverted microscope (Nikon, Tokyo, Japan).
Images were analyzed using the Cell Profiler 3.0 software package [27] and the following functions
to construct the analysis pipelines: Identify Primary Objects, Relate Objects, Filter Objects, Measure
Image Intensity, Measure Object Intensity and Export to Spreadsheet.
2.6. Virus Titration
rKSHV.219 virus containing supernatants was serially diluted in complete media containing
sodium butyrate (1.35 mM, Sigma, St. Louis, MO, USA) and polybrene (8 µg/mL, Sigma). Infection
of U2OS cells with serially diluted viruses was achieved by spinoculation (800× g, 30 min, RT). Next
day, the cells were fixed and stained with an anti-EGFP antibody as described above to identify
rKSHV.219-infected cells. Images were acquired using an ImageXpress Pico microscope (Molecular
Devices, San Jose, CA, USA) or a CellInsight High throughput microscope (Thermo Fischer Scientific).
Images were analyzed using the Cell Profiler 3.0 software package [27] and the following functions
were used to construct the analysis pipelines to count infected cells: Identify Primary Objects, Relate
Objects, Filter Objects and Export to Spreadsheet.
2.7. Quantification of Viral mRNA Transcripts and Genomes
Cellular RNA was extracted using a NucleoSpin RNA extraction kit (Macherey Nagel, Düren,
Germany). RNA was reverse transcribed to cDNA using oligo dT primers and Multiscribe reverse
transcriptase (Thermo Fischer Scientific). cDNA and target primers were mixed with 2X SYBR (Thermo
Fischer Scientific). The genomic DNA was isolated using a Nucleospin Tissue DNA kit (Macherey
Nagel, Düren, Germany). The DNA was mixed with 2X SYBR and primers binding to the genomic
actin and the viral genome at K8.1. The qPCR reactions were conducted in a Light Cycler 480 qPCR
system (Roche, Basel, Switzerland). The primer sequences are listed below:
• Actin-Fw; Rv (5′-tcacccacactgtgccatctacga-3′; 5′-cagcggaaccgctcattgccaatgg-3′);
• ORF50-Fw; -Rv (5′-cacaaaaatggcgcaagatga-3′; 5′-tggtagagttgggccttcagtt-3′);
• ORF45-Fw; Rv (5′-cctcgtcgtctgaaggtga-3′; 5′-gggatgggttagtcaggatg-3′);
• ORF57-Fw; -Rv (5′-tggacattatgaagggcatccta-3′; 5′-cgggttcggacaattgct-3′);
• K8.1-Fw; -Rv (5′-aaagcgtccaggccaccacaga-3′; 5′-ggcagaaaatggcacacggttac-3′);
• Genomic_Actin-Fw; -Rv (5′-agaaaatctggcaccacacc-3′; 5′-aacggcagaagagagaacca-3′).
2.8. RNA Sequencing Analysis
RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA,
USA) was used to determine the RNA integrity. Strand specific poly A enriched mRNA libraries from
total cellular RNA were prepared and sequenced in an Illumina Novaseq 6000 (150 bases, paired end)
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by Novogene (Cambridge, UK). Raw data were cleaned from low quality reads and reads containing
adapter and poly-N-sequences in FASTP [28]. Clean reads were mapped to the human genome
(GRCh38.p12) using HISAT2 with parameters—dta—phred33 [29]. Sequencing reads that remained
unmapped to the human genome were, next, mapped to the KSHV BAC16 [24] (acc: GQ994935), which
is identical to rKSHV.219, using STAR [30]. Read counts were generated by FeatureCounts [31]. The
PANpromoter-RFP, GFP and Puromycin resistance cassette were added to the GQ994935 sequence to
generate the complete rKSHV.219 genome [26]. Raw RNA sequencing data of the viral genes, after
removal of human sequences, were deposited at SRA (acc: PRJNA642085).
2.9. Statistics
One-Way ANOVA and Student’s t tests were performed in Graph Pad Prism v8.0 (San Diego,
CA, USA). For multiple comparison between groups after One-Way ANOVA, Dunnett’s correction
was used.
3. Results
3.1. Targeting the dCas9-Activator to the ORF50 Promoter Induces KSHV Reactivation
We set out to investigate whether a repurposed dCas9 fused to transcription activators can be
guided to the KSHV genome to induce the expression of ORF50 and thereby trigger the complete
KSHV lytic replication cycle. For this, we first generated a HEK293 cell line stably expressing a
conditionally stabilized form of the dCas9-activator, DD-dCas9-VP192. The VP192 domain consists
of 12 copies of the HSV-1 VP16 activator and the destabilizing domain (DD) is derived from the E.
coli DHFR protein [32]. This engineered form of DHFR is highly unstable and can be stabilized by
trimethoprim (TMP) (schematics in Figure 1A). DD-dCas9-VP192 has been previously used to induce
the expression of multiple genes simultaneously to control cell differentiation [21,22]. HEK293 cells,
expressing DD-dCas9-VP192, were then stably infected with rKSHV.219, a double-reporter recombinant
KSHV virus (rKSHV.219). This virus expresses EGFP from a cellular constitutive promoter (EF1α)
and RFP from the PAN viral lytic promoter that is under the control of ORF50 [26]. As a result, EGFP
is expressed in all infected cells while RFP is expressed only in cells where the virus is undergoing
lytic replication. In the generated cell line, we found that in the absence of TMP, DD-dCas9-VP192
(HA tagged) was localized in both the nucleus and cytoplasm, whereas upon addition of TMP, the
stable protein accumulated predominantly in the nucleus. Stabilization and accumulation of the
DD-dCas9-VP192 by TMP was confirmed also by immunoblot analysis (Figure 1B).
We transfected the HEK293-DD-dCas9-VP192-rKSHV.219 cells with plasmids expressing sgRNAs
binding to different regions upstream of the ORF50 gene (−300 bp to −50 bp) (Figure 1C). All four
guides (sg50-1 to sg50-4) were able to induce the KSHV lytic replication cycle, which was initially
detected by the RFP expression (Figure 1C). When compared to non-transfected cells (NT), the mRNA
of ORF50, ORF57 (immediate early), ORF45 (early) and K8.1 (late) were all upregulated. While sg50-1
and -4 induced lower levels of lytic reactivation with fewer RFP+ cells and lower lytic gene expression,
sg50-2 and -3 were more efficient in inducing viral reactivation (Figure 1D). DD-dCas9-VP192-mediated
KSHV reactivation also led to virus production, which was further improved upon DD-dCas9-VP192
stabilization by TMP (Figure 1E). The induction of the KSHV reactivation was not fully controllable
by TMP for two main reasons. First, because DD-dCas9-VP192 partly retains the ability to activate
gene expression also when unstable, as shown previously [21]; and second, when generating the cell
line, the cells infected by rKSHV.219 were initially sorted by FACS to express particularly high levels
of DD-dCas9-VP192.
Overall, these data demonstrate that the dCas9-fused activators can efficiently induce the
expression of ORF50 and the complete lytic cascade leading to virus production.
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upstream of ORF50 start codon (indicated as 0). Lower panels: GFP and RFP expression in
HEK293_DD-dCas9-VP192_rKSHV.219 non-transfected (NT) or transfected with vectors expressing
the indicated sgRNA and treated with TMP (500 nM) for 72 h. RFP is a marker of the rKSHV.219
lytic replication cycle. (D) Quantification of ORF50, ORF57, ORF45 and K8.1 mRNA levels in cells
treated as in (C). Each dot represents a biological replicate, bars show average, error bars show SD. (E)
Quantification of rKSHV.219 titers in the supernatant of HEK293-DD-dCas9-VP192-rKSHV.219 cells
transfected with sg50-2-expressing plasmid and treated with DMSO or TMP (500 nM) for 72 h. Each dot
represents a biological replicate, bars show average, error bars show SD, Student’s t test, *** −p < 0.001.
3.2. Transcriptional Activators Fused to dCas9 Can Trigger the Expression of ORF57 without Affecting
Viral Latency
Activation of ORF57 expression in the early phase of the KSHV lytic cycle is dependent on the
binding of ORF50 to the promoter of ORF57 [33]. We next asked whether DD-dCas9-VP192 can
activate ORF57 gene expression without interrupting virus latency. For this, we generated a set of four
sgRNA-expressing vectors that target positions -53, -128, -200 and -87 (sg57-1 to -4) upstream of the
ORF57 start codon (ATG) in the KSHV genome (Figure 2A), and tested their efficiency in activating the
ORF57 gene expression. Notably, the sgRNA binding at position -87 bp (sg57-4) was able to induce the
strongest expression of ORF57 (Figure 2B). Next, we compared the effect of sg57-4 to that of sg50-2 on
the ORF50 and ORF57 gene expression. At mRNA level, there was a slight increase in the basal ORF50
expression by 2.3 fold in cells expressing ORF57 only (sg57-4). However, this was a negligible increase
when compared to the ORF50 mRNA levels induced by the ORF50-specific sg50-2 which increased
by about 200 fold. ORF57 expression induced by DD-dCas9-VP192 binding upstream of ORF57 was
about five-fold less compared to that expressed during the lytic cycle induced by sg50-2 (Figure 2C).
Accordingly, immunoblot analysis showed high levels of ORF50 and ORF57 proteins upon sg50-2
transfection whereas sg57-4 transfection led to a moderate increase in ORF57 protein levels but no
detectable ORF50 protein, as expected (Figure 2D). In addition, while sg50-2 increased viral genome
copies by about six fold, indicating the progression of the KSHV lytic replication cycle to the late phase,
in the presence of sg57-4, the viral genome copies were unchanged and were comparable to the latent
control (Figure 2E). Similarly, the released infectious virus in the supernatant was detected only upon
sg50-2, but not upon sg57-4 transfection (Figure 2F). RNA-seq analysis confirmed that binding of
DD-dCas9-VP192 upstream of the ORF57 gene upregulated specifically only the expression of ORF57
without affecting expression of adjacent viral genes whereas binding of DD-dCas9-VP192 upstream
of ORF50 led to a global viral gene expression upregulation as expected during KSHV reactivation
(Figure 2G).
This suggests that DD-dCas9-VP192 can be used both to trigger the full KSHV lytic cascade,
with increase in intracellular KSHV genomes and release of infectious virus by targeting the ORF50
promoter and to activate the expression of selected lytic genes (such as ORF57) during KSHV latency.
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Figure 2. Activators fused to dCas9 can trigger the expression of ORF57 without disrupting the viral
latency. (A) A schematic representation of DD-dCas9-VP192 binding sites upstream of the ORF57gene
upon expression of the indicated sgRNAs. Numbers indicate nucleotides upstream of ORF57 start
codon (ATG), shown as 0. (B–G) HEK293_DD-dCas9-VP192_rKSHV.219 cells were transfected with
vectors expressing the indicated sgRNA or left non-transfected (NT) and treated with TMP (500 nM)
for 72 h. (B) Analysis of ORF57 mRNA levels. (C) Analysis of ORF50 and ORF57 mRNA levels.
(D) Immunoblot analysis for the indicated proteins. (E) Quantification of the intracellular KSHV
genome copies. (F) Quantification of rKSHV.219 titers in the supernatant. (G) Heatmap of KSHV gene
expression after RNA-seq analysis of samples in (C) (n = 2 biological replicates). The read counts were
normalized to NT samples and to genome copy numbers calculated in (E). Dark red tiles show values
above 50. (B,C,E,F) Each dot represents a biological replicate, bars show average, error bars show SD.
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3.3. Simultaneous Targeting of the dCas9-Activator at Two Sites on the ORF50 Promoter Further Enhances
KSHV Reactivation
It has been shown that binding of the dCas9-activators to two different sites upstream of a cellular
gene can further improve the target gene expression [21]. To test this in the context of the viral lytic
gene expression, we compared KSHV reactivation in HEK293-DD-dCas9-VP192-rKSHV.219 cells that
were transfected with sg50-2 and sg50-3 separately or as a 1:1 mixture of sg50-2 and sg50-3 (sg50-2+3);
therefore, total amount of DNA transfected in all conditions (mixture vs. single) was equal. In
comparison to sg50-2 or sg50-3 transfected cells, combination of both sgRNAs led to a significant
increase in ORF50, ORF57, ORF45 and K8.1 expression at both mRNA and protein levels (Figure 3A,B).
Next, we found that viral titers reflected the capacity of sg50-2 and sg50-3 to induce ORF50 expression.
Expression of sg50-2 led to slightly higher virus titers than sg50-3, while combining sg50-2 and -3
(sg50-2+3) improved the viral titers significantly with an almost three-fold increase over the single
sgRNAs (Figure 3C). This suggests that targeting DD-dCas9-VP192 at two sites upstream of the ORF50
gene improves the expression of the KSHV lytic proteins and virus production.
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Figure 3. i lta eous targeting of the d as9-activator at t o sites on the F50 pro oter enhances
KSHV reactivation. ( – ) 293_ - as9- 192_r S .219 cells were transfected with vectors
expressing the sgRNA sg50-2, sg50-3, both (sg50-2+3) or left non-transfected (NT) and treated with TMP
(500 nM) for 72 h. (A) Quantificatio of ORF50, ORF57, ORF45 and K8.1 mRNA levels. (B) Immunoblot
analysis for the indicated proteins. (C) Quantification of rKSHV.219 titers in the supernatant. (A and C)
Each dot represents a biological replicate, bars show average, error bars show SD. One-Way ANOVA
followed by Dunnett’s correction for multiple comparisons testing were used to calculate whether
differences between sg50-2, sg50-3 and sg50-2+3 groups were significant (*** −p < 0.001, ** −p < 0.01,
* −p < 0.05).
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3.4. dCas9-Activator Is More Efficient than Ectopic Expression of ORF50 to Induce the Full Viral Lytic
Replication Cycle
To compare the KSHV reactivation efficiency in response to targeting of DD-dCas9-VP192 at the
ORF50 promoter to reactivation induced by ectopic ORF50 expression, we transiently transfected a
vector expressing a Myc-tagged ORF50 or a 1:1 mixture of sg50-2 and sg50-3 vectors (sg50-2+3) in
HEK293-DD-dCas9-VP192-rKSHV. At 72 h post transfection, we observed a slightly higher RFP
expression in the Myc-ORF50 expressing cells over the sg50-2+3 expressing ones (Figure 4A).
Immunoblot analysis showed that while ORF50 protein levels were higher in the Myc-ORF50
transfected cells, the levels of downstream lytic proteins, namely ORF57, ORF45 and K8.1, were
higher in the sg50-2+3 transfected cells (Figure 4B). Moreover, the virus titers were four-fold higher in
the sg50-2+3-transfected cells than in the Myc-ORF50-overexpressing cells (Figure 4C). At single cell
level in the Myc-ORF50-transfected cells, ORF50 was detected in more cells and at higher intensities
than in the HEK293-DD-dCas9-VP192-rKSHV-transfected cells with sg50-2+3. This indicates that
despite higher levels of ORF50, these cells did not undergo a more efficient, productive KSHV lytic
replication (Figure 4D).
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Figure 4. dCas9-activator is more efficient than ectopic expression of ORF50 to induce the viral
lytic replication. (A–D) HEK293_DD-dCas9-VP192_rKSHV.219 cells were transfected with vectors
expressing the sgRNA sg50-2 and sg50-3 (sg50-2+3) or Myc-ORF50 and treated with TMP (500 nM) for
72 h. (A) Representative images showing GFP (upper row) and RFP (lower row) expression of cells
transfected with sg50-2 and sg50-3 (sg50-2+3), Myc-ORF50 or non-transfected (NT). RFP is a marker of
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the rKSHV.219 lytic replication cycle. (B) Immunoblot analysis for the indicated proteins. (C)
Quantification of rKSHV.219 titers in the supernatant. (D) Quantification of ORF50 expression after
staining of the cells with an anti-ORF50 antibody. Nuclei were counterstained with Hoechst 33342.
(C,D) In the violin plot, n > 450 nuclei/condition. In the bar graphs, each dot represents a biological
replicate, bars show average and error bars show SD. Student’s t test was used to calculate whether
differences between Myc-ORF50 and sg50-2+3 groups were significant (** −p < 0.01, *** −p < 0.001).
Together these results show that ORF50 expression driven by dCas9-mediated gene activation
directly from the viral genome can trigger the full KSHV lytic replication program even more efficiently
than ectopic expression of ORF50 in terms of viral lytic protein levels and infectious virus production.
4. Discussion
The use of dCas9, adapted to modulate cellular gene expression, has revealed high potential
in a plethora of applications. Here, we show that dCas9-based activators can be used to efficiently
induce ORF50 expression and consequently the full KSHV lytic replication cascade. When compared
to ectopic expression of ORF50, the DD-dCas9-VP192 induced better both the lytic cycle and virus
production. Additionally, we show that besides ORF50, dCas9-based activators can be targeted to
specifically increase expression of selected KSHV lytic genes, such as ORF57, without driving the full
lytic gene expression program that culminates with virus production.
The promoter of ORF50, a 2.5-kb long region located between the start codons of ORF45 and
ORF50, drives the expression of four different ORF50 isoforms [34]. In this region, there are several
RBP-Jk binding sites that serve to potentiate the effect of ORF50 promoter transactivation by ORF50
itself [35–37] through direct interaction of ORF50 with RBP-Jk [33]. Therefore, by directing the binding
of the large DD-dCas9-VP192 protein (>250 kb) downstream of the RBP-Jk bindings sites could, in
principle, block the RNA polymerase from transcribing the region of ORF50 downstream of the dCas9
binding site. To our surprise, this did not occur. Not only did KSHV lytic gene expression occur
more efficiently but also virus production was not impaired, but rather was enhanced, indicating that
dCas9-activators binding to the viral genome do not interfere with either virus replication or packaging.
To date, lymphatic endothelial cells (LECs) are the only reported cell type where the full KSHV
lytic replication cycle can occur spontaneously [11,12]. We and others have recently shown that this was
partly dependent on the expression of PROX1, which can bind to the ORF50 protein and its promoter
to enhance the lytic replication cycle [25,38]. However, in luciferase-based assays, PROX1 alone was
unable to enhance the basal activity of ORF50 promoter [25], suggesting that other putative transcription
factors expressed in LECs serve to initiate KSHV reactivation in latent cells. Using a dCas9-activator
to mimic the function of these putative transcription factors to start ORF50 expression in latent cell,
we can orchestrate the lytic replication cascade in a similar fashion as the spontaneous reactivation of
KSHV occurs in LECs. Interestingly, when triggered by DD-dCas9-VP192, virus reactivation was even
more efficient than when ORF50 was supplied at higher amounts in the same cellular background.
Therefore, CRISPRa systems may offer a more physiological alternative to trigger the KSHV lytic cycle
as opposed to systems where ORF50 is supplied disproportionally by ectopic expression.
Multiple studies have shown that the ability of dCas9 to bind the DNA is not hampered by fusing
it to other functional domains at either ends of the protein. In fact, in our experiments we used a
dCas9 fused to a destabilizing domain (based on E. coli DHFR) at the N-terminus and an activator
domain (VP192) at the C-terminus to induce ORF50 expression and initiate the viral lytic replication
cycle [19–23,39]. It is conceivable that a dCas9 fused to the activator domain of ORF50 would drive a
more efficient viral reactivation than the DD-dCas9-VP192 used in this study by recruiting (at the ORF50
promoter) authentic ORF50 interaction partners. The ORF50 activator domain is at the C-terminus of
the protein between the amino acids 486-691. This part of the protein binds also to K8 (KbZIP), an early
KSHV protein and transcription factor, which has been shown to modulate KSHV reactivation [40].
Although a KSHV ORF50 transactivation domain fused to dCas9 remains to be tested, a recent study
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used a dCas9 fused to the Epstein-Barr virus (EBV) RTA (highly homologous to KSHV ORF50) together
with VP64 (4 × VP16) and p65 to achieve potent expression of the target genes [39].
In summary, we show that dCas9-activator can be used to induce the full KSHV lytic replication
cascade by directing its binding upstream of the ORF50 gene. In addition, the KSHV-infected HEK293
cell model expressing a dCas9-activator offers a versatile screening platform to identify and validate
new regulators of the KSHV biology. In the future, CRISPRa technology can be applied also to modulate
KSHV gene expression in physiologically relevant KSHV-infected cell models such as PEL-derived cell
lines or human endothelial cells.
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